文献速递泌尿男性生殖肿瘤

仑伐替尼联合帕博利珠单抗对比舒尼替尼一线治疗晚期肾细胞癌(CLEAR):3期随机开放标签研究的延长随访

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
PubMed 文献 · Lancet Oncol · 2023-01-01

CLEAR研究延长随访(数据截止2021年3月31日)显示,在晚期肾细胞癌患者中,仑伐替尼联合帕博利珠单抗对比舒尼替尼的中位无进展生存期为23.3个月 vs 9.2个月(分层HR 0.42,95%CI 0.34-0.52),总生存也获改善(HR 0.72,95%CI 0.55-0.93)。

要点

  • 中位无进展生存期:仑伐替尼联合帕博利珠单抗组23.3个月 vs 舒尼替尼组9.2个月,分层HR 0.42(95%CI 0.34-0.52)。
  • 总生存:仑伐替尼联合帕博利珠单抗组中位未达到(95%CI 41.5-不可估计)vs 舒尼替尼组中位未达到(95%CI 38.4-不可估计),HR 0.72(95%CI 0.55-0.93)。
  • 延长随访显示疗效获益持久且具有临床意义,结果支持仑伐替尼联合帕博利珠单抗作为晚期肾细胞癌一线治疗。

核心结论

  • 延长随访显示,仑伐替尼联合帕博利珠单抗对比舒尼替尼的疗效获益持久且具有临床意义。
  • 这些结果支持仑伐替尼联合帕博利珠单抗作为晚期肾细胞癌患者的一线治疗。

研究设计与样本

  • CLEAR是一项开放标签、3期、随机试验,本次为方案预设的总生存更新分析(数据截止2021年3月31日)。
  • 纳入既往未接受过任何系统性抗癌治疗(包括抗血管内皮生长因子治疗)或任何系统性研究性抗癌药物的透明细胞晚期肾细胞癌患者,来自20个国家200个中心(医院和癌症中心)。
  • 患者按1:1:1随机分配至仑伐替尼联合帕博利珠单抗组、仑伐替尼联合依维莫司组(本次更新分析未报告)或舒尼替尼组。
  • 2016年10月13日至2019年7月24日筛查1417例,随机分配1069例(75%;女性273例[26%],男性796例[74%];中位年龄62岁[IQR 55-69]);仑伐替尼联合帕博利珠单抗组355例(33%;男性255例[72%],女性100例[28%]),舒尼替尼组357例(33%;男性275例[77%],女性82例[23%]),仑伐替尼联合依维莫司组357例(33%,本次更新分析未报告)。
  • 主要终点为独立影像学评审根据RECIST v1.1评估的无进展生存期;本次报告意向治疗人群的延长随访无进展生存期和方案预设的总生存更新数据,本次随访未进行安全性分析。

主要发现

  • 无进展生存期中位随访时间:仑伐替尼联合帕博利珠单抗组27.8个月(IQR 20.3-33.8),舒尼替尼组19.4个月(IQR 5.5-32.5)。
  • 中位无进展生存期:仑伐替尼联合帕博利珠单抗组23.3个月(95%CI 20.8-27.7)vs 舒尼替尼组9.2个月(95%CI 6.0-11.0),分层HR 0.42(95%CI 0.34-0.52)。
  • 总生存中位随访时间:仑伐替尼联合帕博利珠单抗组33.7个月(IQR 27.4-36.9),舒尼替尼组33.4个月(IQR 26.7-36.8)。
  • 总生存:仑伐替尼联合帕博利珠单抗组中位未达到(95%CI 41.5-不可估计)vs 舒尼替尼组中位未达到(95%CI 38.4-不可估计),HR 0.72(95%CI 0.55-0.93)。

关键数值与推荐

  • 仑伐替尼联合帕博利珠单抗组给药方案:仑伐替尼20 mg每日口服,21天为一周期;帕博利珠单抗200 mg静脉注射,每21天一次。
  • 舒尼替尼组给药方案:舒尼替尼50 mg每日口服,服药4周、停药2周。
  • 随机分配按地理区域和Memorial Sloan Kettering Cancer Center预后分组进行分层。
  • 入组患者年龄至少18岁,Karnofsky体能状态评分70或以上。

临床怎么用

  • 作者结论认为,这些结果支持仑伐替尼联合帕博利珠单抗作为晚期肾细胞癌患者的一线治疗。

局限性

  • 本次随访未进行安全性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the primary analysis of the CLEAR study, lenvatinib plus pembrolizumab significantly improved progression-free survival and overall survival versus sunitinib in patients with advanced renal cell carcinoma (data cutoff Aug 28, 2020). We aimed to assess overall survival based on 7 months of additional follow-up. METHODS: This is a protocol-prespecified updated overall survival analysis (data cutoff March 31, 2021) of the open-label, phase 3, randomised CLEAR trial. Patients with clear-cell advanced renal cell carcinoma who had not received any systemic anticancer therapy for renal cell carcinoma, including anti-vascular endothelial growth factor therapy, or any systemic investigational anticancer drug, were eligible for inclusion from 200 sites (hospitals and cancer centres) across 20 countries. Patients were randomly assigned (1:1:1) to receive lenvatinib (20 mg per day orally in 21-day cycles) plus pembrolizumab (200 mg intravenously every 21 days; lenvatinib plus pembrolizumab group), lenvatinib (18 mg per day orally) plus everolimus (5 mg per day orally; lenvatinib plus everolimus group [not reported in this updated analysis]) in 21-day cycles, or sunitinib (50 mg per day orally, 4 weeks on and 2 weeks off; sunitinib group). Eligible patients were at least 18 years old with a Karnofsky performance status of 70 or higher. A computer-generated randomisation scheme was used, and stratification factors were geographical region and Memorial Sloan Kettering Cancer Center prognostic groups. The primary endpoint was progression-free survival assessed by independent imaging review according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). In this Article, extended follow-up analyses for progression-free survival and protocol-specified updated overall survival data are reported for the intention-to-treat population. No safety analyses were done at this follow-up. This study is closed to new participants and is registered with ClinicalTrials.gov, NCT02811861. FINDINGS: Between Oct 13, 2016, and July 24, 2019, 1417 patients were screened for inclusion in the CLEAR trial, of whom 1069 (75%; 273 [26%] female, 796 [74%] male; median age 62 years [IQR 55-69]) were randomly assigned: 355 (33%) patients (255 [72%] male and 100 [28%] female) to the lenvatinib plus pembrolizumab group, 357 (33%) patients (275 [77%] male and 82 [23%] female) to the sunitinib group, and 357 (33%) patients to the lenvatinib plus everolimus group (not reported in this updated analysis). Median follow-up for progression-free survival was 27·8 months (IQR 20·3-33·8) in the lenvatinib plus pembrolizumab group and 19·4 months (5·5-32·5) in the sunitinib group. Median progression-free survival was 23·3 months (95% CI 20·8-27·7) in the lenvatinib plus pembrolizumab group and 9·2 months (6·0-11·0) in the sunitinib group (stratified hazard ratio [HR] 0·42 [95% CI 0·34-0·52]). Median overall survival follow-up was 33·7 months (IQR 27·4-36·9) in the lenvatinib plus pembrolizumab group and 33·4 months (26·7-36·8) in the sunitinib group. Overall survival was improved with lenvatinib plus pembrolizumab (median not reached [95% CI 41·5-not estimable]) versus sunitinib (median not reached [38·4-not estimable]; HR 0·72 [95% CI 0·55-0·93]). INTERPRETATION: Efficacy benefits of lenvatinib plus pembrolizumab over sunitinib were durable and clinically meaningful with extended follow-up. These results support the use of lenvatinib plus pembrolizumab as a first-line therapy for patients with advanced renal cell carcinoma. FUNDING: Eisai and Merck Sharp & Dohme.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Choueiri TK, Eto M, Motzer R, et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 2023. PMID: 36858721. doi:10.1016/S1470-2045(23)00049-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。